THE MAMMAPRINT® AND BLUEPRINT® DIFFERENCE
Agendia’s tests can identify premenopausal women with low risk of metastasizing to avoid possible overtreatment. In fact, Level 1 evidence shows the majority of women with a MammaPrint UltraLow1 result did not receive chemotherapy, and the distant metastasis free interval was
97% at 5 years.2
Everyone’s breast cancer is unique so having a personalized treatment plan is critical. Watch the videos below to see how we are working to provide tests that help guide customized treatment plans that work for our patients wherever they are on their journey, regardless of menopausal status or age.3
Consistent results you can trust.
PERIOD. OR NO PERIOD.
DEVELOPING PERSONALIZED TREATMENT PLANS WITH AGENDIA
William Audeh, MD,
Chief Medical Officer
A PATIENT’S JOURNEY WITH INDIVIDUALIZED CARE
Summer,
Cancer Survivor
REVOLUTIONIZING BREAST CANCER DIAGNOSIS
WITH GENE EXPRESSION PROFILING
Victoria Poillucci, DNP,
Breast Cancer Nurse Educator
THE MAMMAPRINT AND BLUEPRINT DIFFERENCE
Betsy Hanna,
Chief Commercial Officer
- Cardozo J, et al 022. JCO
- Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. Josephine M.N. Lopes Cardozo, Caroline A. Drukker, Emiel J.T. Rutgers, Marjanka K. Schmidt, Annuska M.
Glas, Anke Witteveen, Fatima Cardoso, Martine Piccart, Laura J. Esserman, Coralie Poncet, and Laura J. van ‘t Veer. Journal of Clinical Oncology 2022 40:12, 1335-1345 - MammaPrint® FFPE is FDA-cleared for 18 years or older.
- Results should be taken in the context of other relevant clinico-pathological factors and standard practice of medicine
